ANAVEX LIFE SCIENCES CORP. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
ANAVEX LIFE SCIENCES CORP. (AVXL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $5.30 million for the 12-month period ending 2025-09-30, per its 10-K/A filed 2026-08-28.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-08-28
- ANAVEX LIFE SCIENCES CORP. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2025 was $5.30M, a 23.26% increase from fiscal 2024.
- ANAVEX LIFE SCIENCES CORP. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $4.30M, a 0.00% change from fiscal 2023.
- ANAVEX LIFE SCIENCES CORP. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $4.30M, a 95.45% increase from fiscal 2022.
- ANAVEX LIFE SCIENCES CORP. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $2.20M, a 37.50% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month as first filed |
|---|---|---|
| 2025-09-30 | $5.30M 10-K/A · filed 2026-08-28 | |
| 2024-09-30 | $4.30M 10-K · filed 2024-12-23 | |
| 2023-09-30 | $4.30M 10-K/A · filed 2026-08-28 | $2.70M 10-K · filed 2023-11-27 |
| 2022-09-30 | $2.20M 10-K · filed 2023-11-27 | |
| 2021-09-30 | $1.60M 10-K · filed 2022-11-28 | |
| 2020-09-30 | $2.10M 10-K · filed 2021-11-24 | |
| 2018-09-30 | -$77.00K 10-K · filed 2019-01-25 | |
| 2017-09-30 | -$23.00K 10-K · filed 2019-01-25 | |
| 2016-09-30 | $628.00K 10-K · filed 2019-01-25 | |
| 2015-09-30 | $502.00K 10-K · filed 2017-12-11 | |
| 2014-09-30 | -$26.00K 10-K · filed 2016-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |